Moderna

Pharma companies like Novo Nordisk, Viking Therapeutics, Amgen, CRISPR Therapeutics, and Moderna are set to announce clinical trial results for next-gen weight loss drugs, cancer and autoimmune therapies, and potential new products beyond COVID-19 vaccines by year-end.

Asia is rapidly becoming a biomanufacturing powerhouse, with countries like China, Singapore, South Korea, and India leading the charge. These nations are investing heavily in infrastructure, fostering innovation, and improving regulatory environments to attract global biopharma investments. The Asia Pacific biopharmaceuticals market is projected to grow significantly, driven by government support, skilled workforce development, and strategic partnerships. Key initiatives include Singapore's BioPIPS, South Korea's Bio-Health Industry Promotion Plan, Australia's RNA Sector Development Plan, and India's BioE3 Policy, all aimed at enhancing biomanufacturing capabilities and positioning Asia as a global leader in the biopharma industry.

The FDA updates mRNA COVID-19 vaccines for 2024-2025 to include KP.2 strain of Omicron JN.1 lineage, aiming for better protection. Updated vaccines available for all age groups, with specific dose recommendations based on vaccination history. Both Pfizer and Moderna confirm immediate availability.

Penn Engineers developed siloxane-incorporating lipid nanoparticles (SiLNPs) that enhance mRNA delivery to specific tissues like the liver, lungs, and spleen, potentially revolutionizing personalized medicine and gene therapy.

Study investigates pre-operative mRNA-based models for predicting biochemical recurrence (BCR) in prostate cancer, finding machine learning (ML) models, particularly random survival forest (RSF) and boosted Cox models, significantly outperform traditional nomograms. mRNA variables like DNAH8, ABCC11, ESM1, and PI15 show potential as biomarkers for early treatment decisions, paving the way for precision medicine approaches.

Moderna has initiated its Phase III Nova 301 trial for mRNA-1403, a norovirus vaccine, aiming to assess efficacy, safety, and immunogenicity globally. The trial will enroll 25,000 adults, focusing on regions including the US, Canada, the UK, Japan, Australia, and South America. mRNA-1403 targets multiple norovirus genotypes and aims to prevent severe gastroenteritis, particularly in older adults.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.

Penn Engineers developed siloxane-incorporating lipid nanoparticles (SiLNPs) that can target specific organs like the liver, lungs, and spleen, enhancing mRNA delivery and potentially revolutionizing precision medicine and gene therapy.

Xtalks offers free webinars on biomarkers, cell and gene therapy, clinical trials, drug discovery, and more. Topics include automated biomarker detection, CAR T therapy beyond oncology, and AI in drug discovery. Register for free at http://www.xtalks.com.

Roivant Sciences Ltd. (NASDAQ:ROIV) is a healthcare company with a market cap of $8.51 billion, focusing on drug development through technology and strategic partnerships. It ranks 2nd on a list of best small company stocks to invest in, with potential growth driven by successful clinical trials and strategic deals, such as a $1.2 billion deal for its Dermavant business. Analysts predict small-cap stocks, including ROIV, could benefit from lower interest rates and outperform large-cap stocks.